175 related articles for article (PubMed ID: 29610282)
1. SKLB-23bb, A HDAC6-Selective Inhibitor, Exhibits Superior and Broad-Spectrum Antitumor Activity via Additionally Targeting Microtubules.
Wang F; Zheng L; Yi Y; Yang Z; Qiu Q; Wang X; Yan W; Bai P; Yang J; Li D; Pei H; Niu T; Ye H; Nie C; Hu Y; Yang S; Wei Y; Chen L
Mol Cancer Ther; 2018 Apr; 17(4):763-775. PubMed ID: 29610282
[TBL] [Abstract][Full Text] [Related]
2. SKLB-14b, a novel oral microtubule-destabilizing agent based on hydroxamic acid with potent anti-tumor and anti-multidrug resistance activities.
Zhang W; Yang L; Si W; Tang M; Bai P; Zhu Z; Kuang S; Liu J; Shi M; Huang J; Chen X; Li D; Wen Y; Yang Z; Xiao K; Chen L
Bioorg Chem; 2022 Nov; 128():106053. PubMed ID: 35964504
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
Yang Z; Wang T; Wang F; Niu T; Liu Z; Chen X; Long C; Tang M; Cao D; Wang X; Xiang W; Yi Y; Ma L; You J; Chen L
J Med Chem; 2016 Feb; 59(4):1455-70. PubMed ID: 26443078
[TBL] [Abstract][Full Text] [Related]
4. 2-Methylquinazoline derivative 23BB as a highly selective histone deacetylase 6 inhibitor alleviated cisplatin-induced acute kidney injury.
Hao Y; Guo F; Huang Z; Feng Y; Xia Z; Liu J; Li L; Huang R; Lin L; Ma L; Fu P
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894849
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cell migration and induction of apoptosis by a novel class II histone deacetylase inhibitor, MCC2344.
Dawood M; Fleischer E; Klinger A; Bringmann G; Shan L; Efferth T
Pharmacol Res; 2020 Oct; 160():105076. PubMed ID: 32659428
[TBL] [Abstract][Full Text] [Related]
6. Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models.
Depetter Y; Geurs S; De Vreese R; Goethals S; Vandoorn E; Laevens A; Steenbrugge J; Meyer E; de Tullio P; Bracke M; D'hooghe M; De Wever O
Int J Cancer; 2019 Aug; 145(3):735-747. PubMed ID: 30694564
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth.
Van Helleputte L; Kater M; Cook DP; Eykens C; Rossaert E; Haeck W; Jaspers T; Geens N; Vanden Berghe P; Gysemans C; Mathieu C; Robberecht W; Van Damme P; Cavaletti G; Jarpe M; Van Den Bosch L
Neurobiol Dis; 2018 Mar; 111():59-69. PubMed ID: 29197621
[TBL] [Abstract][Full Text] [Related]
8. Selective Histone Deacetylase 6 Inhibitor 23BB Alleviated Rhabdomyolysis-Induced Acute Kidney Injury by Regulating Endoplasmic Reticulum Stress and Apoptosis.
Feng Y; Huang R; Guo F; Liang Y; Xiang J; Lei S; Shi M; Li L; Liu J; Feng Y; Ma L; Fu P
Front Pharmacol; 2018; 9():274. PubMed ID: 29632491
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of quinazoline derivatives as dual HDAC1 and HDAC6 inhibitors for the treatment of cancer.
Chen J; Sang Z; Jiang Y; Yang C; He L
Chem Biol Drug Des; 2019 Mar; 93(3):232-241. PubMed ID: 30251407
[TBL] [Abstract][Full Text] [Related]
10. ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.
Wang F; Zhong BW; Zhao ZR
J Biol Regul Homeost Agents; 2018; 32(4):851-858. PubMed ID: 30043566
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel PAK1/HDAC6 dual inhibitor ZMF-23 that triggers tubulin-stathmin regulated cell death in triple negative breast cancer.
Zhang J; Chen X; Chen G; Wang H; Jia L; Hao Y; Yao D
Int J Biol Macromol; 2023 Nov; 251():126348. PubMed ID: 37586623
[TBL] [Abstract][Full Text] [Related]
12. Neuronal complexity is attenuated in preclinical models of migraine and restored by HDAC6 inhibition.
Bertels Z; Singh H; Dripps I; Siegersma K; Tipton AF; Witkowski WD; Sheets Z; Shah P; Conway C; Mangutov E; Ao M; Petukhova V; Karumudi B; Petukhov PA; Baca SM; Rasenick MM; Pradhan AA
Elife; 2021 Apr; 10():. PubMed ID: 33856345
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase 6 promotes growth of glioblastoma through the MKK7/JNK/c-Jun signaling pathway.
Huang Z; Xia Y; Hu K; Zeng S; Wu L; Liu S; Zhi C; Lai M; Chen D; Xie L; Yuan Z
J Neurochem; 2020 Jan; 152(2):221-234. PubMed ID: 31390677
[TBL] [Abstract][Full Text] [Related]
14. MIL-1, a novel antitumor agent derived from natural product millepachine, acts as tubulin polymerization inhibitor for the treatment of hepatocellular carcinoma.
Yan J; Zhuang Q; Li Z; Xiong Y; He M; Kang C; Zhang Q; Han L; Liang E; Liu H; Ke P; Huang X
Eur J Pharmacol; 2021 May; 898():173975. PubMed ID: 33647258
[TBL] [Abstract][Full Text] [Related]
15. High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma.
Liu JR; Yu CW; Hung PY; Hsin LW; Chern JW
Biochem Pharmacol; 2019 May; 163():458-471. PubMed ID: 30885763
[TBL] [Abstract][Full Text] [Related]
16. A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth.
Kaliszczak M; Trousil S; Åberg O; Perumal M; Nguyen QD; Aboagye EO
Br J Cancer; 2013 Feb; 108(2):342-50. PubMed ID: 23322205
[TBL] [Abstract][Full Text] [Related]
17. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y
Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303
[TBL] [Abstract][Full Text] [Related]
18. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
[TBL] [Abstract][Full Text] [Related]
19. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.
Xiang Q; Zhen Z; Deng DY; Wang J; Chen Y; Li J; Zhang Y; Wang F; Chen N; Chen H; Chen Y
J Exp Clin Cancer Res; 2015 Oct; 34():118. PubMed ID: 26458953
[TBL] [Abstract][Full Text] [Related]
20. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
